However, in our study, we observed an interesting trend, namely that, after CPT treatment, both ORR and CBR were notably higher in patients who had received more than three prior treatments than in patients who had received three or fewer prior treatments (ORR, 46.2% vs. 21.4%; CBR, 61.5% vs. 35.7%).
← all excerpts
Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma.
1
—
—